Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01189 (
beta-endorphin
)
21,003
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cutaneous lupus erythematosus
(
CLE
) is a heterogeneous autoimmune disease involving well-defined skin lesions that can be categorized as acute
CLE
(ACLE), subacute
CLE
(SCLE), chronic
CLE
(CCLE), or intermittent
CLE
(ICLE). It is commonly accepted that ultraviolet (UV) exposure can induce and exacerbate skin lesions in patients with certain subtypes of
CLE
. Phototesting with UVA and UVB irradiation using a standardized protocol has proven to be a reliable model to study photosensitivity in
CLE
and to analyse the underlying pathomechanisms of the disease. In addition to UV-mediated induction of apoptosis, the molecular and cellular factors that may underlie the abnormal long-lasting photoreactivity in
CLE
include mediators of inflammation such as cytokines and chemokines, inducible nitric oxide (NO) synthase (iNOS), and cellular adhesion molecules. The photosensitivity associated with
CLE
requires education of the patient about avoidance of excessive sun exposure, continuous photoprotection through physical measures such as protective clothing, and daily application of broad-spectrum sunscreens. Novel approaches to UV-protection, such as
alpha-MSH
or thymidine dinucleotides, might also have an impact on photosensitivity in patients with
CLE
. In this review, we summarize the current knowledge about photosensitivity in patients with
CLE
, including an overview of standardized phototesting procedures, possible molecular pathomechanisms, and photoprotection.
...
PMID:Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. 2069 97